Mahmoud Yousefifard, Atousa Janzadeh, Kosar Mohamed Ali, Mohammad Hossein Vazirizadeh-Mahabadi, Arash Sarveazad, Arian Madani Neishaboori, Mostafa Hosseini
{"title":"Chondroitinase ABC Administration in Locomotion Recovery After Spinal Cord Injury: A Systematic Review and Meta-analysis.","authors":"Mahmoud Yousefifard, Atousa Janzadeh, Kosar Mohamed Ali, Mohammad Hossein Vazirizadeh-Mahabadi, Arash Sarveazad, Arian Madani Neishaboori, Mostafa Hosseini","doi":"10.32598/bcn.2021.1422.1","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The present systematic review and meta-analysis aims to conduct a comprehensive and complete search of electronic resources to investigate the role of administrating Chondroitinase ABC (ChABC) in improving complications following Spinal Cord Injuries (SCI).</p><p><strong>Methods: </strong>MEDLINE, Embase, Scopus, and Web of Sciences databases were searched until the end of 2019. Two independent reviewers assessed the studies conducted on rats and mice and summarized the data. Using the STATA 14.0 software, the findings were reported as pooled standardized mean differences (SMD) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>A total of 34 preclinical studies were included. ChABC administration improves locomotion recovery after SCI (SMD=0.90; 95% CI: 0.61 to 1.20; P<0.001). The subgroup analysis showed that the differences in the SCI model (P=0.732), the severity of the injury (P=0.821), the number of ChABC administrations (P=0.092), the blinding status (P=0.294), the use of different locomotor score (P=0.567), and the follow-up duration (P=0.750) have no effect on the efficacy of ChABC treatment.</p><p><strong>Conclusion: </strong>The findings of the present study showed that prescribing ChABC has a moderate effect in improving locomotion after SCI in mice and rats. However, this moderate effect introduces ChABC as adjuvant therapy and not as primary therapy.</p>","PeriodicalId":8701,"journal":{"name":"Basic and Clinical Neuroscience","volume":"13 5","pages":"609-624"},"PeriodicalIF":1.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/da/BCN-13-609.PMC10258590.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/bcn.2021.1422.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 1
Abstract
Introduction: The present systematic review and meta-analysis aims to conduct a comprehensive and complete search of electronic resources to investigate the role of administrating Chondroitinase ABC (ChABC) in improving complications following Spinal Cord Injuries (SCI).
Methods: MEDLINE, Embase, Scopus, and Web of Sciences databases were searched until the end of 2019. Two independent reviewers assessed the studies conducted on rats and mice and summarized the data. Using the STATA 14.0 software, the findings were reported as pooled standardized mean differences (SMD) with 95% confidence intervals (CI).
Results: A total of 34 preclinical studies were included. ChABC administration improves locomotion recovery after SCI (SMD=0.90; 95% CI: 0.61 to 1.20; P<0.001). The subgroup analysis showed that the differences in the SCI model (P=0.732), the severity of the injury (P=0.821), the number of ChABC administrations (P=0.092), the blinding status (P=0.294), the use of different locomotor score (P=0.567), and the follow-up duration (P=0.750) have no effect on the efficacy of ChABC treatment.
Conclusion: The findings of the present study showed that prescribing ChABC has a moderate effect in improving locomotion after SCI in mice and rats. However, this moderate effect introduces ChABC as adjuvant therapy and not as primary therapy.
引言：本系统综述和荟萃分析旨在对电子资源进行全面、完整的检索，以研究给予软骨素酶ABC（ChABC）在改善脊髓损伤（SCI）并发症中的作用。方法：检索MEDLINE、Embase、Scopus和Web of Sciences数据库，直到2019年底。两名独立评审员评估了在大鼠和小鼠身上进行的研究，并总结了数据。使用STATA 14.0软件，将结果报告为95%置信区间（CI）的合并标准化平均差（SMD）。结果：共纳入34项临床前研究。ChABC给药可改善SCI后的运动恢复（SMD=0.90；95%CI:0.61-1.20；P结论：本研究结果表明，在小鼠和大鼠SCI后，开ChABC对改善运动有中等效果。然而，这种中等效果将ChABC作为辅助治疗而非主要治疗。
期刊介绍：
BCN is an international multidisciplinary journal that publishes editorials, original full-length research articles, short communications, reviews, methodological papers, commentaries, perspectives and “news and reports” in the broad fields of developmental, molecular, cellular, system, computational, behavioral, cognitive, and clinical neuroscience. No area in the neural related sciences is excluded from consideration, although priority is given to studies that provide applied insights into the functioning of the nervous system. BCN aims to advance our understanding of organization and function of the nervous system in health and disease, thereby improving the diagnosis and treatment of neural-related disorders. Manuscripts submitted to BCN should describe novel results generated by experiments that were guided by clearly defined aims or hypotheses. BCN aims to provide serious ties in interdisciplinary communication, accessibility to a broad readership inside Iran and the region and also in all other international academic sites, effective peer review process, and independence from all possible non-scientific interests. BCN also tries to empower national, regional and international collaborative networks in the field of neuroscience in Iran, Middle East, Central Asia and North Africa and to be the voice of the Iranian and regional neuroscience community in the world of neuroscientists. In this way, the journal encourages submission of editorials, review papers, commentaries, methodological notes and perspectives that address this scope.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
